Ymmunobio AG

The core activity of Ymmunobio is the development of preclinical cancer therapeutics, particularly antibodies that influence the immune system and directly inhibit cancer cells. The company focuses on developing innovative treatments for cancer patients, especially for solid tumors, and has already made progress in developing antibodies that reactivate the immune system and directly inhibit cancer cells.